SG Americas Securities LLC acquired a new position in shares of Harrow, Inc. (NASDAQ:HROW – Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 11,874 shares of the company’s stock, valued at approximately $534,000.
A number of other institutional investors also recently bought and sold shares of HROW. Private Capital Management LLC increased its position in shares of Harrow by 97.2% in the fourth quarter. Private Capital Management LLC now owns 2,794,497 shares of the company’s stock valued at $31,298,000 after buying an additional 1,377,597 shares in the last quarter. Woodmont Investment Counsel LLC increased its holdings in Harrow by 73.3% during the 1st quarter. Woodmont Investment Counsel LLC now owns 211,579 shares of the company’s stock valued at $2,799,000 after acquiring an additional 89,510 shares in the last quarter. Wasatch Advisors LP raised its position in Harrow by 28.3% during the first quarter. Wasatch Advisors LP now owns 388,132 shares of the company’s stock worth $5,135,000 after acquiring an additional 85,600 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Harrow by 66.0% in the first quarter. China Universal Asset Management Co. Ltd. now owns 6,745 shares of the company’s stock valued at $89,000 after purchasing an additional 2,682 shares in the last quarter. Finally, BNP Paribas Financial Markets grew its position in shares of Harrow by 12.7% in the first quarter. BNP Paribas Financial Markets now owns 16,941 shares of the company’s stock valued at $224,000 after purchasing an additional 1,912 shares during the last quarter. 72.76% of the stock is currently owned by hedge funds and other institutional investors.
Harrow Stock Up 5.1 %
Shares of NASDAQ HROW opened at $53.49 on Wednesday. The firm has a market cap of $1.89 billion, a P/E ratio of -58.78 and a beta of 0.75. The company has a debt-to-equity ratio of 3.18, a quick ratio of 2.43 and a current ratio of 2.60. Harrow, Inc. has a 1 year low of $7.60 and a 1 year high of $54.31. The firm’s 50 day moving average price is $42.73 and its 200 day moving average price is $26.42.
Wall Street Analysts Forecast Growth
Several research analysts recently issued reports on HROW shares. Lake Street Capital lifted their price objective on Harrow from $45.00 to $55.00 and gave the stock a “buy” rating in a research report on Friday, October 4th. B. Riley reissued a “buy” rating and issued a $50.00 price target on shares of Harrow in a report on Thursday, August 29th. Finally, Craig Hallum increased their price objective on Harrow from $45.00 to $65.00 and gave the company a “buy” rating in a research note on Friday, October 4th.
Read Our Latest Stock Analysis on Harrow
Harrow Profile
Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.
Read More
- Five stocks we like better than Harrow
- Stock Market Sectors: What Are They and How Many Are There?
- Goldman Sachs Earnings Reveal Market Moves Investors Can’t Ignore
- Trading Halts Explained
- AMD Gains Momentum With AI: Can It Beat Expectations?
- Stock Analyst Ratings and Canadian Analyst Ratings
- Lithium Grab: 2 Lithium Stocks That Could Be Takeover Targets
Want to see what other hedge funds are holding HROW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Harrow, Inc. (NASDAQ:HROW – Free Report).
Receive News & Ratings for Harrow Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow and related companies with MarketBeat.com's FREE daily email newsletter.